Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
about
Atypical hemolytic uremic syndromeEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndromeHemolytic uremic syndrome: new developments in pathogenesis and treatmentCritical appraisal of eculizumab for atypical hemolytic uremic syndromeAdvances and challenges in the management of complement-mediated thrombotic microangiopathiesCurrent state of renal transplant immunosuppression: Present and futureCurrent treatment of atypical hemolytic uremic syndromeIdiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.Clinical grand rounds: atypical hemolytic uremic syndrome.Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.The use of eculizumab in renal transplantation.Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case reportReduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case reportThe role of complement in the early immune response to transplantation.Novel immunosuppressive agents in kidney transplantationAn emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.Innate immunity in solid organ transplantation: an update and therapeutic opportunities.Primary disease recurrence—effects on paediatric renal transplantation outcomes.Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Atypical hemolytic uremic syndrome
P2860
Q21202864-90482CED-08F7-4AE2-8B53-D13114C0E051Q24605432-20577706-23D7-4801-9116-9AAD40A46345Q24613517-27C85C4A-DC13-4829-B581-101C4BA479A4Q26750692-019460EE-6C2E-4ED3-81EA-6CB42FA81023Q26796453-23FBA4B6-9AE7-44B3-8B89-3ABEE3C000CAQ26829789-1A30419D-6816-4A75-9AFE-C9D5920553CEQ27003211-C10E4FCC-C0C9-4FD1-8E8A-F323F392D46EQ33398967-7394DFC8-9F05-44C1-815F-72F565B7FB68Q33400834-32E5B6CB-B2A6-42E2-BAFF-D3936B92D624Q33402795-0BAEA0A7-06C8-4347-AC65-61C20E0AA7D6Q33403196-43F7B9DE-3AE2-4E9C-9E1F-6FB227673969Q33403359-571FF93F-A28C-4952-B7C1-7A205A8CD600Q33403607-6DE16A76-ADC4-4453-95E7-83C958B755EEQ33406025-FF4ED1F4-8927-4B24-ADDD-F1860610F963Q33406570-3635398B-4ED3-4A6A-B1A0-725650B6D2B5Q33407344-1B205638-FE3B-4B82-B1B0-88AEAB8F5A14Q33408733-F1C4096D-A095-478E-9600-3D9F3E4399C4Q33417655-BC7B544F-9E39-422E-AC8E-425C51570D8FQ35683974-D3D7A0EA-191B-4DED-87D1-5D19683C6C08Q38013049-86C6E158-531E-4F2C-971E-3F1566077747Q38176005-3ED25B6C-DEE0-4C97-A00D-A6FEDB94AFEFQ38232593-1766E040-C346-4D0E-9CEC-15F837062533Q38341632-E2AEF4C3-5E4E-4EF9-A303-A0F2BCBA83E8Q38445275-ED6CEB78-3F28-4FC5-97C2-4F5EFB5854B3Q39112532-ADD33523-63FC-4304-B1F5-11C99F59E0E4Q40654455-74FD9BDD-DD7F-40BC-A542-2E8AC0B754A2Q46159176-247E16E0-D8EE-4611-B665-F85FB61FE854Q48102410-D04919F7-1D89-4EDB-A630-489123E5A4CDQ56591965-E9DCEACD-8B9C-4A17-97EE-3F7A19BF78AD
P2860
Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@ast
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@en
type
label
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@ast
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@en
prefLabel
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@ast
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@en
P2093
P1476
Eculizumab: safety and efficac ...... -uremic syndrome: case report.
@en
P2093
B Hurault de Ligny
J Ph Ryckelynck
T Lobbedez
V Châtelet
V Frémeaux-Bacchi
P304
P356
10.1016/J.TRANSPROCEED.2010.09.125
P407
P577
2010-12-01T00:00:00Z